Valneva SE (VALN) Earnings
Valneva SE is expected to report next earnings on November 19, 2026 (in NaN days), with a consensus EPS estimate of $-0.17. VALN has beaten EPS estimates in 4 of its last 12 reported quarters (average surprise -71.2% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 13, 2026 | $-0.28 | $-0.40 | -42.9% | $40M | -16.4% |
| May 13, 2026 | $-0.21 | $-0.42 | -100.0% | $36M | -33.8% |
| Mar 18, 2026 | $-0.17 | $-0.24 | -38.7% | $55M | -0.5% |
| Nov 20, 2025 | $-0.30 | $-0.61 | -103.3% | $34M | -29.5% |
| Aug 12, 2025 | $-0.27 | $-0.16 | +40.7% | $57M | +45.5% |
| Mar 20, 2025 | $-0.22 | $-0.54 | -145.5% | $55M | +49.4% |
| Nov 7, 2024 | $-0.30 | $-0.15 | +50.0% | $50M | -10.1% |
| Mar 20, 2024 | $0.20 | $-0.50 | -350.0% | $46M | -40.0% |
| Nov 9, 2023 | $-0.51 | $-0.54 | -5.9% | $40M | -10.9% |
| Sep 21, 2023 | $-0.36 | $-0.26 | +27.8% | $44M | +27.4% |
| May 4, 2023 | $-0.35 | $-0.28 | +20.0% | $36M | +10.0% |
| Mar 23, 2023 | $0.29 | $-0.65 | -324.1% | $120M | -24.2% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 13, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
### Financial Position and Restructuring - Valneva ended H1 2026 with a strong cash position of 121.5 million euros, built via disciplined cash management and proceeds from a recent equity offering. - A broad restructuring program was implemented in June 2026, including workforce reduction, project reprioritization, and focus on core operations. One-time restructuring costs of 3.2 million euros were recorded in H1 2026, with positive P&L and cash flow impacts expected in H2 2026 and beyond. - R&D expenses decreased to 30.2 million euros from 32.4 million euros H1 2025, and marketing/distribution expenses decreased to 13.5 million euros from 20.3 million euros H1 2025, driven by R&D rescheduling and planned advertising/promotion cuts. - Operating loss for H1 2026 was 49.9 million euros, compared to a 16.8 million euro operating loss in H1 2025; adjusted EBITDA loss was 40.1 million euros, compared to a 6 million euro loss H1 2025, driven primarily by non-recurring first-half costs. ### Lyme Disease Vaccine (VLA15 / LB6V) - The Phase III trial demonstrated >70% point efficacy and a strong safety profile, with the lower bound of the 95% confidence interval exceeding 20% in a second pre-specified analysis, despite missing the original lower bound statistical threshold. - Pfizer expects regulatory decisions for the candidate within the next 12 months, and has already completed a regulatory submission to the European Medicines Agency; the FDA submission is in progress, with both regulatory processes proceeding independently. - There is a large unmet medical need: ~500,000 annual cases in the U.S. and >100,000 underreported annual cases in Europe, with 10-30% of cases resulting in severe complications and 5-10% of patients having persistent symptoms after treatment. LB6V is the only late-stage Lyme vaccine candidate and would be the first new Lyme vaccine in 30 years if approved. ### Other Pipeline and Commercial Updates - For XCHIK (chikungunya vaccine), the company shifted focus to access in endemic low- and middle-income countries (LMICs). A locally manufactured version by partner Butantan has been approved in Brazil and is expected to be added to Brazil's public health system soon. A pilot vaccination campaign has vaccinated over 50,000 adults to date, targeting 100,000 total for active pharmacovigilance expected to complete by late 2026. Valneva is evaluating a revised commercial strategy focused on endemic markets given slow travel segment uptake. - Valneva has in-licensed the most clinically advanced tetravalent Shigella vaccine candidate, currently running two trials (immunogenicity/safety in infants, controlled human infection model efficacy in adults). Results are expected in the coming months, after minor delays from the former program owner's acquisition; next development steps will be announced after data readout. - The company's long-term strategic direction is to leverage its vaccine development expertise to build a risk-balanced pipeline of high-value vaccine assets beyond vector-borne diseases, including ongoing work on internal early-stage candidates (EBV, ETEC, antimicrobial resistance targets), and to maximize cash generation from existing commercial operations to reinvest in R&D.
Guidance
- Management maintains full-year 2026 guidance, with projected product sales of 135 to 150 million euros and total revenues of 145 to 160 million euros, as H1 2026 sales were in line with anticipated pacing. - A new contract with the U.S. Department of Defense for Ixiaro supply is expected to be signed in the coming months, with sales under the new contract starting in H2 2026. - Product gross margins are expected to improve significantly in H2 2026 after the non-recurring, one-time adverse impacts recorded in H1 2026. Full-year 2026 gross margin will not reach 2025 levels but will be much closer than H1 2026 results, with further improvement expected in 2027. - The previously guided 25% to 35% operating expense reduction versus 2025 remains in place, with no upward or downward revision. - Valneva expects to achieve financial self-sustainability starting in 2027, pending successful regulatory approval and commercialization of the Lyme disease vaccine by partner Pfizer.
Segment performance
Total product sales for H1 2026 were 64 million euros, down from 91 million euros in H1 2025. Total company revenues reached 65.8 million euros, compared to 97.6 million euros in H1 2025. 1. Ixiaro: H1 2026 sales of 44 million euros, down from 54.7 million euros H1 2025. Contributed 68.75% of total product sales. Gross margin was 56.4%, down from 65.5% H1 2025, driven by lower volumes and unfavorable manufacturing scheduling changes. 2. Ducoral: H1 2026 sales of 14.7 million euros, down from 17.4 million euros H1 2025. Contributed 22.97% of total product sales. Gross margin was 24.7%, down from 52.9% H1 2025, impacted by higher-than-usual failed batch costs and inventory revaluation. 3. XCHIK (IXCHIC): H1 2026 sales of 4.4 million euros, down from 7.5 million euros H1 2025. Contributed 6.88% of total product sales. Gross margin was negative due to one-time non-cash impacts: a 9.7 million euro provision for manufacturing cancellation fees and a 4.5 million euro inventory impairment, with no cash impact from these items. 4. Third-party products: H1 2026 sales of 1 million euros, down from 11.4 million euros H1 2025, from planned non-renewal of key distribution agreements that ended in December 2025.
Risks & headwinds
- The Lyme disease vaccine missed the lower bound of the pre-specified 95% confidence interval in the initial Phase III analysis, creating regulatory and approval uncertainty. The success of Valneva's long-term strategy and financial self-sufficiency is heavily dependent on successful approval and commercial performance of the Lyme vaccine. - Slow uptake of XCHIK in the travel vaccine market has led to excess inventory, manufacturing contract cancellation costs, and negative gross margin, requiring a strategic re-evaluation of the product's commercial path. - Shigella vaccine trial results have been delayed by operational changes stemming from the acquisition of the original program developer, creating uncertainty around near-term development timelines. - Foreign currency fluctuations have had an adverse impact on Ixiaro sales, and geopolitical factors have weakened travel vaccine demand in some regions, negatively impacting Ducoral sales. - The ongoing transition to a new distributor in Germany created demand absorption from existing legacy inventory, reducing reported sales for both Ixiaro and Ducoral in H1 2026.
Analyst Q&A
Q: What additional details can you share on Lyme vaccine regulatory progress, including the economics of any potential additional Phase III or post-marketing studies? /
A: Pfizer is making good progress with global regulators, and no further details can be shared at this time. Under the existing agreement, Valneva only shares development costs up to licensure; any post-licensure activities are not covered by the current contract. Decisions on further Valneva investment in additional Lyme vaccine activities will not occur until after the product is licensed. Regulator submissions to the EMA and FDA are proceeding as independent parallel processes, with EMA (Europe) expected to conclude first.
Q: What is causing the delay to Shigella vaccine data readout, and will you provide a clear path forward after data is released? /
A: Minor delays stem from operational cleanup after the original program developer Nematheque was acquired by Didi. The company is in the final stages of data validation and analysis, and results will be released soon. After data from the two trials (human challenge efficacy in adults, safety/immunogenicity in children) is available, Valneva will decide whether to proceed to the next development stage or optimize the candidate's schedule/formulation, and will announce next steps alongside or shortly after data disclosure. No additional regulatory feedback from agencies is needed at this stage.
Q: Does Valneva's strategic shift to a more R&D-focused biotech model depend entirely on Lyme vaccine success, and what cost savings come from the Nantes site sale? /
A: Valneva will remain fully integrated, as commercial and manufacturing capabilities benefit vaccine development, but the core strategic goal is to maximize cash from commercial operations to reinvest in R&D. The scale of R&D investment and ability to reach financial self-sustainability depends heavily on Lyme approval and commercial success, which would provide milestone and royalty revenue to fund pipeline expansion. Consolidation of R&D operations to Vienna (closing the Nantes site) will generate ongoing long-term efficiency and cost reductions, alongside one-time proceeds from the site building sale.
Q: What is the timeline for commercial launch of the locally approved Butantan-produced XCHIK vaccine in Brazil, and how long will the pilot vaccination program run? /
A: Butantan is still completing launch planning, so it is too early to give a firm commercial launch timeline, though there is clear government intent to add the vaccine to Brazil's public health system and the opportunity is expected to be significant. The pilot pharmacovigilance program is run by Brazil's Ministry of Health, which targets a minimum of 100,000 vaccinated people, a milestone expected to be reached by the end of 2026.